

Interim report July-September 2022

A challenging third quarter

Quarter July-September 2022

- ▶ Net sales amounted to SEK 125.6 (111.8) million, an increase of 12.4 percent. Adjusted for currency effects, a decrease of -8.1 percent.
- ▶ The number of instruments sold amounted to 803 (996), a decrease by 19.4 percent.
- ▶ Operating profit was SEK 3.6 (13.0) million, corresponding to an operating margin of 2.9 (11.7) percent.
- ▶ Profit for the period amounted to SEK 2.4 (7.1) million.
- ▶ Basic earnings per share amounted to SEK 0.12 (0.37) and diluted earnings per share amounted to SEK 0.12 (0.36).
- ▶ Cash flow from operating activities amounted to SEK -15.8 (10.6) million.
- ▶ Net debt on September 30 amounted to SEK 73.7 million compared to last year when it was SEK 6.5 million.
- ▶ August 4th it was announced that Annette Colin leaves the Boule Diagnostics CFO position due to family reasons.
- ▶ September 6th it was announced that Clinical Diagnostic Solutions, Inc. (CDS), a subsidiary to Boule Diagnostics AB, has been issued a Notice of Inspectional Observations (FDA Form 483) by the US Food and Drug Administration (the FDA).

Key figures	Jul-Sep 2022	Jul-Sep 2021	Jan-Sep 2022	Jan-Sep 2021	Oct 21-Sep 22 (R12)	Oct 20-Sep 21 (R12)
Sales growth, %	12.4	13.2	23.5	5.0	-4.9	-4.9
Net sales, SEK million	125.6	111.8	398.9	323.1	539.2	415.7
Gross margin, %	40.7	44.7	40.4	43.6	40.6	43.3
Operating profit (EBIT), SEK million	3.6	13.0	18.9	22.2	32.7	-19.5
Operating margin (EBIT), %	2.9	11.7	4.7	6.9	6.1	-4.7
Profit after tax, SEK million	2.4	7.1	9.8	6.0	27.1	-26.6
Net debt, SEK million	73.7	6.5	73.7	6.5	73.7	6.5
Return on equity, %	0.7	2.7	3.1	2.2	8.7	-9.8
Net debt/EBIT (R12), times	2.2	-0.3	2.2	-0.3	2.2	-0.3
Diluted earnings per share, SEK	0.12	0.36	0.49	0.30	1.40	-0.33

Dynamisk graf: Net sales and EBIT, rolling 12 months

Q4 2020 incl. a write-down of intangible assets of SEK 40 million.

NEXT 